Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

1(20%)

Results Posted

50%(2 trials)

Phase Distribution

Ph phase_3

20%

Ph phase_4

20%

Ph phase_1

20%

Ph phase_2

20%

Ph early_phase_1

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Early Phase 1First-in-human

1(20.0%)

Phase 1Safety & dosage

1(20.0%)

Phase 2Efficacy & side effects

1(20.0%)

Phase 3Large-scale testing

1(20.0%)

Phase 4Post-market surveillance

1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(4)

Detailed Status

Completed4

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (20.0%)

Phase 11 (20.0%)

Phase 21 (20.0%)

Phase 31 (20.0%)

Phase 41 (20.0%)

Trials by Status

recruiting120%

completed480%

Recent Activity

1 active trials

Showing 5 of 5

recruitingearly_phase_1

The Effect of an α2-Adrenoceptor Antagonist (Yohimbine) on Dynamic Autoregulation in the Human Middle Cerebral Artery and Ophthalmic Artery

NCT00814047

Clinical Trials (5)

Showing 5 of 5 trials

NCT06430580Early Phase 1

Cannabinoids and Biological Reactivity to Stress

Recruiting

NCT00078715Phase 2

Rapid Antidepressant Effects of Yohimbine in Major Depression

Completed

NCT03670212Phase 1

Investigation of Nicotine Seeking Behavior in Current Smokers

Completed

NCT00958880Phase 3

Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety

Completed

NCT00814047Phase 4

The Effect of an α2-Adrenoceptor Antagonist (Yohimbine) on Dynamic Autoregulation in the Human Middle Cerebral Artery and Ophthalmic Artery

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5